Last reviewed · How we verify
NCT05419102
Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)
trial testing peri-implantitis surgery with enamel matrix derivative in Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment in 34 participants. Completed in 6 June 2022.
15 May 2022
Quick facts
| Lead sponsor | North Dallas Dental Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 34 |
| Start date | 1 April 2022 |
| Primary completion | 15 May 2022 |
| Estimated completion | 6 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- peri-implantitis surgery with enamel matrix derivative
Conditions studied
- Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment — all drugs for Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment →
Sponsor
North Dallas Dental Health
Who can join
Adults 18 to 90, any sex, with Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The existing records of a private practice limited to the practice of periodontology were reviewed to locate patients who had been diagnosed with peri-implantitis (failing dental implant) and had been surgically treated utilizing enamel matrix derivative (Commercially available FDA product Emdogain sold by Straumann USA). Various clinical factors were gathered from the existing records. Some of the factors recorded were: retention of the implant, presence of bleeding, presence of further damage, and presence of inflammation. All patients had signed an informed consent for treatment and the anonymous use of their data for research purposes. All HIPA requirements were followed.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Use of Enamel Matrix Derivative during Surgical Therapy for Peri-Implantitis: A Case Series.
Wilson TG, Harrel SK, Nunn ME. · · 2023 · cited 3× · PMID 38248219 · DOI 10.3390/dj12010011 -
The Effect of Age and Use of Enamel Matrix Derivative on Implant Loss.
Harrel SK, Wilson TG, Nunn ME, Cobb CM. · · 2026 · PMID 41590187 · DOI 10.3390/dj14010063
Verify or expand the search:
- PubMed search for NCT05419102
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05419102 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by North Dallas Dental Health
- Last refreshed: 15 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05419102.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing